At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 123 enrolled
Drug / intervention
LY2140023 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Short-Term, Multicenter, Placebo-Controlled, Randomized Withdrawal Study of LY2140023 Monohydrate in Patients With DSM-IV-TR Schizophrenia
In Brief
A Phase 3 clinical trial evaluating LY2140023 and Placebo for Schizophrenia. Completed, enrolled 123 participants across 10 sites in 2 countries.
Detailed Summary
The purpose of this study is to determine whether or not people with schizophrenia who take LY2140023 become physically dependent on it, and experience a series of symptoms such as craving to have the drug when they stop using it. This trial consists of two phases: An open-label phase consisting of up to 4 weeks and a double-blind phase consisting of up to 3 weeks.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesGreece, United States
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedOct 2011
Enrollment StartNov 2011
Primary CompletionSep 2012
TodayJul 2026
First PostedOct 17, 2011
Enrollment StartNov 1, 2011
Primary CompletionSep 1, 2012
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 14.7 years ago
Interventions
LY2140023drug
Administered orally
Placebodrug
Administered orally